HilleVax – Talk Bio

Actionable Insights Powered by AI

Royalty Market Accelerates with XOMA Biotech Acquisitions and OrbiMed’s Major Fundraise

1 month ago talkbio0Tagged Arenaria, Biological Factors, Biological Science Disciplines, biopharma financing, Conditional, HilleVax, Investments, LAVA, M&A, mezigitamab, OrbiMed, royalty acquisition, XOMA Royalty

royalty acquisition; XOMA Royalty; biotech M&A; OrbiMed; biopharma financing; mezigitamab; Turnstone Biologics; HilleVax; LAVA Therapeutics; contingent value rights; life sciences investment

HilleVax Discontinues Norovirus Vaccine for Infants After Mid-Stage Trial Failure

1 year ago talkbio0Tagged Discontinuation (procedure), Failure (biologic function), HilleVax, Infant, mid-stage trial, Norovirus, Vaccines

HilleVax, norovirus vaccine, infants, mid-stage trial, failure, discontinuation